By Fineline Cube 
A recent clinical study published by Eli Lilly & Co. (NYSE: LLY) demonstrates that the GLP‑1 agonist Mounjaro (tirzepatide) can help children as young as 10 manage blood sugar and achieve significant weight loss. The trial, involving roughly 100 pediatric patients (ages 10‑17), reported an average 2 % reduction in HbA1c and a 10 % decline in body weight after one year of therapy.
Study Highlights
- Blood‑glucose control: Average HbA1c fell by ~2 %.
- Weight loss: Participants lost > 10 % of baseline body weight.
- Safety profile: No new safety signals; tolerability comparable to adults.
Regulatory Strategy
Eli Lilly has submitted the data to global drug regulators with the goal of expanding Mounjaro’s label to pediatric type 2 diabetes. Approval would mark the first GLP‑1 product specifically cleared for children with this condition—a growing public‑health concern linked to rising obesity rates.
Competitive Landscape
- Novo Nordisk is also testing its GLP‑1 agents (Wegovy, Saxenda, Ozempic) in children as young as 6.
- Wegovy & Saxenda are currently approved for obesity in patients ≥ 12 years in the U.S. and EU.
- Ozempic remains unapproved for pediatric use, leaving a regulatory gap that Mounjaro could fill.
Market Implications
If cleared, Mounjaro would broaden Eli Lilly’s portfolio into a niche market projected to reach $4 billion by 2030, driven by the increasing prevalence of childhood obesity and type 2 diabetes. The drug’s dual action—glucose lowering and weight reduction—aligns with clinicians’ call for more aggressive early interventions.-Fineline Info & Tech